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In vivoa b s t r a c t
Apelin peptide analogues displaying bias towards G protein signalling pathways have beneficial cardio-
vascular actions compared with the native peptide in humans in vivo. Our aim was to determine whether
small molecule agonists could retain G protein bias. We have identified a biased small molecule, CMF-
019, and characterised it in vitro and in vivo.
In competition radioligand binding experiments in heart homogenates, CMF-019 bound to the human,
rat and mouse apelin receptor with high affinity (pKi = 8.58 ± 0.04, 8.49 ± 0.04 and 8.71 ± 0.06 respec-
tively). In cell-based functional assays, whereas, CMF-019 showed similar potency for the Gai pathway
to the endogenous agonist [Pyr1]apelin-13 (pD2 = 10.00 ± 0.13 vs 9.34 ± 0.15), in b-arrestin and internal-
isation assays it was less potent (pD2 = 6.65 ± 0.15 vs 8.65 ± 0.10 and pD2 = 6.16 ± 0.21 vs 9.28 ± 0.10
respectively). Analysis of these data demonstrated a bias of 400 for the Gai over the b-arrestin pathway
and 6000 over receptor internalisation. CMF-019 was tested for in vivo activity using intravenous injec-
tions into anaesthetised male Sprague–Dawley rats fitted with a pressure-volume catheter in the left ven-
tricle. CMF-019 caused a significant increase in cardiac contractility of 606 ± 112 mmHg/s (p < 0.001) at
500 nmol. CMF-019 is the first biased small molecule identified at the apelin receptor and increases car-
diac contractility in vivo. We have demonstrated that Gai over b-arrestin/internalisation bias can be
retained in a non-peptide analogue and predict that such bias will have the therapeutic benefit following
chronic use. CMF-019 is suitable as a tool compound and provides the basis for design of biased agonists
with improved pharmacokinetics for treatment of cardiovascular conditions such as pulmonary arterial
hypertension.
 2016 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The apelin receptor is a class A G protein-coupled receptor first
cloned in 1993 [1] and was deorphanised in 1998 when its cognate
ligand, apelin, was identified from bovine stomach extracts [2]. The
predominant isoform in the human cardiovascular system is [Pyr1]
apelin-13 [3]. Infusion of apelin leads to vasodilatation, in humans
in vitro [3] and in vivo [4] and in rodents in vivo [5], as well as car-
diac inotropy in vitro [3,6,7] and in vivo in rats [8–10], mice [11]
and humans [12] without hypertrophy.These properties of apelin signalling have made it of particular
interest as a potential therapeutic for a number of diseases such as
pulmonary arterial hypertension (PAH) and heart failure (HF) [13].
Moreover, there is significant evidence to suggest that whilst the
apelin peptide is downregulated in both PAH [14–16] and HF
[17–19], expression of the receptor remains unchanged and
responsive to apelin [15,20,21]. This provides an opportunity to
replace the downregulated endogenous agonist in a therapeutic
setting. Previous work has shown that infusion of apelin is benefi-
cial in a number of disease models of PAH [22] and HF [8–10,23–
25], but long term therapeutic efficacy is limited by a short half-
life of a few minutes. Oral therapy for these chronic diseases would
necessitate a compound with longer half-life. Furthermore, upon
activation of the receptor, bound apelin is rapidly internalised
through the b-arrestin pathway with the rate of recycling back to
the plasma membrane highly dependent on the ligand [26,27].
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efficacy.
We hypothesise that a G protein biased small molecule apelin
agonist could provide a solution to this limitation. We have previ-
ously designed apelin peptide analogues that are G protein biased
and this strategy resulted in an improved duration of action and
increased efficacy [4]. Alteration of a specific serine residue
(Ser348) in the apelin receptor has been shown to abolish the G pro-
tein receptor kinase/b-arrestin pathway signalling whilst preserv-
ing signalling through the G protein pathway. It has also been
reported that removal of the C-terminal phenylalanine of apelin-
17 can induce bias towards G protein signalling [28]. These reports
suggest that the apelin receptor is tractable to biased signalling
[29]. Here we identify CMF-019, a small molecule, which binds
to the human apelin receptor with high affinity, exerts a biased
response through the G protein pathway and mimics the beneficial
cardiovascular actions of apelin in rodents.2. Methods
2.1. Materials
Chemicals were obtained from Sigma–Aldrich Co. Ltd (Poole,
UK) unless otherwise stated. [Pyr1]apelin-13 (Glp-
RPRLSHKGPMPF) was from Severn Biotech (Kidderminster, UK),
[Glp65,Nle75,Tyr77][125I]apelin-13, was from Perkin Elmer (MA,
USA). CMF-019 was synthesised in the School of Chemistry,
University of Leeds. Human tissues were obtained with informed
consent from the Papworth Hospital Research Tissue Bank (08/
H0304/56) and ethical approval (05/Q104/142) and conformed to
the principles outlined in the declaration of Helsinki. Animal
experiments were performed in accordance with guidelines from
the local ethics committee (University of Cambridge) and the
Home Office (UK) under the Scientific Procedures Act (1986).2.2. Homology modelling of the apelin receptor/apelin-13 and ligand
receptor docking of CMF-019
A homology model was constructed from the 2.5 Å resolution
crystal structure of the human CXCR4 chemokine receptor. MOD-
ELLER9v8 was used to generate homology models of apelin which
were subsequently refined using molecular dynamics. A more
detailed description of the procedure is given in Brame et al.
(2015) [4]. Water and ions were removed in preparation for dock-
ing studies. The model of CMF-019 (carboxylic acid ionised) was
constructed using Sybyl 7.3 and energy minimised in vacuo using
the TriposFF and Gasteiger-Huckel charges. Docking was per-
formed using the programme GOLD (CCDC 2015) [30,31].
It was hypothesised that the agonist, CMF-019, occupied a site
in close proximity to the site occupied by apelin-13 within the
pocket formed by the seven transmembrane helices of the recep-
tor. However, initial docking of CMF-019 into this long pocket
formed from the receptor model resulted in a number of possible
solutions. To constrain the system, we utilised the previously
determined homology model of bound apelin-13 [4], selecting
the region containing the serine-histidine-lysine (SHK) sequence
of apelin-13 as the most promising region for binding of CMF-
019 (which is adjacent to the important residue Tyr88 identified
from mutagenesis studies). A receptor cavity composed of residues
up to 12 Å from the SHK region of apelin-13 was used for docking.
The ChemPLP scoring function was used with standard GOLD
settings.2.3. Synthesis of CMF-019
CMF-019 ((S)-3-[1-(1-Ethyl-propyl)-2-thiophen-2-ylmethyl-
1H-benzoimidazole-5-carbonyl]-amino-5-methyl-hexanoic acid)
has previously been prepared (compound number 107 from patent
US20140094450, 2014) via a minor modification of the literature
procedure (Fig. 2) [32]. For in vivo studies we used the potassium
salt of the compound (Fig. 1) dissolved in saline at pH9 as it
showed better solubility than the parent compound. Thermody-
namic solubility (potassium salt) and an in vitro murine microso-
mal stability of CMF-019 were performed at Cyprotex
(Macclesfield, UK).
2.4. Competition radioligand binding
Initial binding assays were performed by Cerep (Celle L’Eves-
cault, France) on Chinese Hamster Ovary (CHO-K1) cells expressing
the human apelin receptor. Further experiments were performed
on human homogenised left ventricle (HLV, 1.5 mg/ml) and rat
and mouse whole heart homogenates to determine any species
variability prior to in vivo experiments. Competition binding exper-
iments were carried out using [Glp65,Nle75,Tyr77][125I]apelin-13
(0.1 nmol/L) as described previously [4], with unlabelled CMF-
019 (2 pmol/L-10 lmol/L) as the competitive agonist. Binding in
the presence of 2 lmol/L [Pyr1]apelin-13 was considered non-
specific. Experiments were performed in triplicate and data anal-
ysed using GraphPad Prism 6 (GraphPad Software, Inc. La Jolla,
USA). Binding affinities were calculated by the Cheng-Prusoff
methodology using measured IC50 values.
2.5. Cell-based assays
b-Arrestin recruitment, b-arrestin mediated internalisation and
cAMP assays were performed according to the manufacturer’s
instructions (DiscoverX, Fremont, CA) and as described previously
[4]. Agonist responses, measured in relative light units, were
expressed as a percentage relative to the EMAX of [Pyr1]apelin-13
for b-arrestin and internalisation experiments and as a percentage
relative to the forskolin response for cAMP experiments. Data were
fitted to a four parameter model using GraphPad Prism 6 and the
pD2 (log10 of the EC50 (the concentration producing 50% of the
maximum response)) and maximum response (EMAX) values were
calculated and compared.
2.6. Rat heart catheterisation and jugular vein cannulation for in vivo
assessment of CMF-019
Male Sprague–Dawley rats (273 ± 6 g; Charles River Laborato-
ries, Margate, UK) were induced to anaesthesia with inhalation of
3% isoflurane and then maintained under 1.5% isoflurane via a face
mask. Temperature was monitored throughout the surgical proce-
dure using a rectal probe. Prior to the start of surgery, it was
ensured that pain reflexes had ceased by use of a hind-paw pinch
test. The surgery was completed as previously described [33]. In
brief, the right external jugular vein was cannulated, flushed with
heparin solution (2%, 0.9% saline, pH5, Macopharma) and the right
common carotid artery located. The catheter (Millar Inc., SPR-869)
was calibrated using the MPVS Ultra system (ADIstruments) before
being inserted into the carotid and advanced to the left ventricle.
Once a stable pressure–volume loop could be observed, the cathe-
ter was left in place for ten minutes. Three cumulative bolus doses
of CMF-019 (50–5000 nmol, 0.5 mL, 0.9% saline, pH9, Macopharma,
n = 7–9) were then administered intravenously, followed by a sal-
ine flush (0.9%, 0.1 mL, pH5) via the cannula at ten minute inter-
vals, so that a stable baseline was reached before the next
injection. The effects on pressure and volume were measured
Fig. 1. Structure of the potassium salt of CMF-019.
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depth of anaesthesia. Control animals were injected with saline
(0.9%, 0.5 mL, pH9) and a flush of equal volume (0.9%, 0.1 mL,
pH5) to distinguish the drug effects from any volume effects
(n = 3–5). The effects of [Pyr1]apelin-13 (50, 400 nmol, 0.5 mL,Fig. 2. Synthetic pathway for the production of the potassium salt of CMF-019. Intermedi
aminopentane)-4-nitrobenzylmethanoate, (4) Methyl-3-amino-4-(pentan-3-ylamino)b
zole-5-carboxylate, (6) 1-(Pentan-3-yl)-2-(thiophen-2-ylmethyl)-1H-benzo[d]imidazole
aminopentane, DMF, (c) 5% Pd/C, H2 (15 bar), MeOH, (d) 2-thiophene acetic acid, SOCl2, D
HCTU, DIPEA, DMF, (ii) NaOH, MeOH, (h) KOH, 1,4-dioxane.0.9% saline, pH5, Macopharma, n = 8) were studied for comparison.
Animals were randomly chosen to receive CMF-019, saline or
[Pyr1]apelin-13 injection. Data were acquired using the MPVS Ultra
system (ADIstruments) and analysed using LabChart 8 (ADIstru-
ments). Values for the maximal change in left ventricular systolic
pressure (LVSP), stroke volume, cardiac output, contractility (dP/
dtMAX) and lusitropy (dP/dtMIN) from baseline were calculated from
the raw data and compared. Following completion of the measure-
ments the animal was euthanised by exsanguination under high
flow isoflurane.2.7. Analysis of plasma samples by mass spectrometry
Analysis of plasma samples was performed by Peakdale Molec-
ular (Chapel-en-la-Frith, UK). End-point blood samples were taken
from rats (n = 6) following completion of three cumulative doses of
CMF-019 (as described before), approximately 10 min after the lastates: (1) 4-fluoro-3-nitrobenzoic acid, (2) Methyl-4-fluoro-3-nitrobenzoate, (3) 3-(3-
enzoate, (5) Methyl-1-(pentan-3-yl)-2-(thiophen-2-ylmethyl)-1H-benzo[d]imida-
-5-carboxylic acid. Reagents and conditions: (a) SOCl2, MeOH, (b) K2CO3, 3-
CM, (e) acetic acid, 140 C (microwave), (f) NaOH, MeOH, 110 C (microwave), (g) (i)
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coated vials and spun at low speed (2000 g, 5 min), the plasma
supernatant was removed and frozen. Quantitative analysis was
performed using LC-MS/MS with metaprolol as an internal stan-
dard and CMF-019 to quantify CMF-019 in the samples.2.8. Computational assessment of oral drug properties
CMF-019 was assessed for drug-like properties using FAF-
Drugs3 [34]. This compared the properties of CMF-019 to a library
of oral drugs and predicted its physiochemical properties accord-
ing to Lipinski’s and Verber’s rules. In addition, CMF-019 was anal-
ysed using a principal component analysis (PCA) of 15 key
physiochemical properties and compared to the properties of oral
drugs in current use, extracted as sublibraries from the databases,
eDrugs and DrugBank.2.9. Statistical analysis
All data are expressed as mean ± SEM values. Binding and cell-
based experiments were performed in triplicate. For cell based
assays, n-values are given as the number of replicates/number of
experiments. Bias calculations were performed, as previouslyFig. 3. Computational docking of CMF-019. A 2D interaction map (A) showing the bindin
are p-stacking (thiophene to Tyr88, green line) and ionic (carboxylate to Arg168, purple lin
(B). The key binding interactions between the ligand and APJ receptor (at Arg168 and Ty
favoured overlay of apelin 13 (red lines) with CMF-019 (grey lines) (C) places CMF-019 at
region for binding of CMF-019 to the APJ receptor. (For interpretation of the references todescribed [35], to obtain values for relative effectiveness of CMF-
019 compared to [Pyr1]apelin-13 within each cell-based assay
and bias factors calculated to compare the relative activities of
the agonists between different pathways. For the in vivo study, values
for the cardiovascular parameters measured in saline and CMF-019
treated animals were compared using two-tailed student’s t-test
(GraphPad Prism 6). Statistical significance was taken as 5%.3. Results
3.1. Computational docking of CMF-019
CMF-019 bound into a mainly hydrophobic cavity on the apelin
receptor near the SHK region of bound apelin-13. The carboxylic
acid of CMF-019 was predicted to form a strong hydrogen bond
(2.3 Å) with the side-chain of Arg168. The thiophene, which is
important for maintenance of good potency, formed a p-stacking
interaction with residue Tyr88. A ligand/protein plot of these close
interactions between CMF-019 and the apelin receptor was gener-
ated (Fig. 3A), as well as a close up view of the ligand receptor
interactions (Fig. 3B). To compare the similarity in the expected
binding regions of CMF-019 and the predicted apelin-13 docked
structure, they were overlaid (Fig. 3C).g site and interactions between CMF-019 and the APJ receptor. The key interactions
es) bonds. CMF-019 (pale blue sticks) docked via GOLD into the APJ receptor (green)
r88) are highlighted (dotted yellow lines) with intermolecular distances shown. The
the SHK region, suggesting that the SHK sequence of apelin-13 is the most promising
colour in this figure legend, the reader is referred to the web version of this article.)
Table 1
Values of DLogR and relative effectiveness (RE) for CMF-019 compared to [Pyr1]
apelin-13 in cAMP, b-arrestin and internalisation assays.
DLogR RE
b-Arrestin 1.98 ± 0.18 0.01
Internalisation 3.14 ± 0.19 7.19  104
cAMP 0.62 ± 0.16 4.19
DLogR is Log10(s/KA) where s is a measure of agonist efficacy and KA a measure of
functional affinity [35]. n values for each of the assays are as indicated in Fig. 5.
Table 2
DDLogR and bias factors (BF, in bold) for CMF-019 compared [Pyr1]apelin-13 in cAMP,
b-arrestin and internalisation assays.
DDLogR BF b-Arrestin Internalisation
b-Arrestin n/a 1.17 ± 0.26
15
cAMP 2.60 ± 0.24 3.77 ± 0.25
398 5828
DDLogR is the difference between DLogR values in the different pathways [35].
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CMF-019 bound to the human apelin receptor expressed in CHO
cells with nanomolar affinity (pKi = 7.61 ± 0.14). In human left ven-
tricle, CMF-019 showed monophasic competition and a ten-fold
higher binding affinity to the native apelin receptor
(pKi = 8.58 ± 0.04, Fig. 4A). Similar binding was observed in rat
and mouse heart (pKi = 8.49 ± 0.04, Fig. 4B; pKi = 8.71 ± 0.06,
Fig. 4C respectively).
3.3. CMF-019 displays G protein bias
CMF-019 induced b-arrestin recruitment (Fig. 5B) to the apelin
receptor (pD2 = 6.65 ± 0.15, n = 13/4) and subsequent receptor
internalisation (Fig. 5C) (pD2 = 6.16 ± 0.21, n = 6/2) but was less
potent than [Pyr1]apelin-13 (pD2 = 8.65 ± 0.10, n = 12/4;
pD2 = 9.28 ± 0.10, n = 6/2 respectively). In contrast, CMF-019
potently inhibited Gai-mediated cAMP production (Fig. 5A)
(pD2 = 10.00 ± 0.13, n = 11/4), comparable to [Pyr1]apelin-13
(pD2 = 9.34 ± 0.15, n = 8/4). In all assays, EMax values for CMF-019
were similar to those obtained for [Pyr1]apelin-13 suggesting that
the compound acted as a full agonist at the apelin receptor.
To quantify the degree to which CMF-019 displayed bias com-
pared to the reference agonist [Pyr1]apelin-13, relative effective-
ness (RE) and bias factors (BF) were calculated as described
previously [35] and are shown in Tables 1 and 2 respectively.
3.4. CMF-019 is a positive inotrope in vivo
Injection of CMF-019 caused a dose dependent increase in the
dP/dtMAX, a measure of cardiac contractility, with significance at
500 nmol of 606 ± 112 mmHg/s (p < 0.001) and at 5000 nmol of
833 ± 152 mmHg/s (p < 0.01) (Fig. 6A). [Pyr1]apelin-13 also caused
a dose dependent increase with a significant response at 400 nmol
of 3025 ± 680 mmHg/s (P < 0.01) (Fig. 6B). [Pyr1]apelin-13 dose
dependently caused a significant increase in stroke volume and
cardiac output up to a response at 400 nmol of 9.18 ± 0.86RVUFig. 4. Competition binding experiments in heart tissue homogenates. The specific bi
homogenate (B, j) and mouse whole heart homogenate (C, N).
Fig. 5. Pathway selectivity of CMF-019 determined from cell-based assays. The concentra
dn = 8/4, jn = 11/4), b-arrestin (B, dn = 12/4, jn = 13/4) and internalisation (C, dn =
effectiveness (RE) and bias factors (BF) are shown in Tables 1 and 2 respectively.(P < 0.0001) and 3989 ± 537RVU/min (P < 0.001) respectively.
CMF-019 similarly increased these parameters with smaller
responses detected. Changes at 500 nmol of 2.62 ± 0.31RVU
(P < 0.05) and 1210 ± 170RVU/min (P < 0.01) respectively were sig-
nificant (Fig. 7A,C). Neither [Pyr1]apelin-13 nor CMF-019 altered
the dP/dtMIN, a measure of lusitropy (Fig. 7E-F). [Pyr1]apelin-13
caused a significant dose dependent drop in the LVSP with a max-
imal drop of 15.7 ± 1.8 mmHg detected at 400 nmol (P < 0.01)
(Fig. 7G), however, CMF-019 resulted in a dose dependent increase
in pressure with a significant increase of 6.22 ± 1.98 mmHg at
5000 nmol (P < 0.05) (Fig. 7H). A limitation of this study was the
relatively low solubility of CMF-019 (potassium salt) in saline
(2.09 mg/mL at pH7.4) that did not allow higher doses to be
infused. No adverse effects were observed at any of the concentra-
tions administered.nding of CMF-019 to human left ventricular homogenate (A, d), rat whole heart
tion response curves for [Pyr1]apelin-13 (d) and CMF-019 (j) in cell-based cAMP (A,
6/2, jn = 6/2) assays. Bias was calculated as described previously [35], relative
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CMF-019 had a half-life of 38 min in the in vitromicrosomal sta-
bility experiment. Analysis of the plasma samples taken from rats
treated with CMF-019 (potassium salt) demonstrated a mean
plasma concentration of 25.4 ± 2.5 lM (heparinised samples,
n = 6).
3.6. CMF-019 demonstrates good physiochemical properties for an oral
drug
Analysis of CMF-019 using FAF-Drugs3 [34] demonstrated a
good physiochemical profile when compared to an oral drug
library for Lipinski’s rules (Fig. 8A), Verber’s rules (Fig. 8B) and in
a PCA analysis of 15 physiochemical descriptors (Fig. 8C). CMF-
019 had only one Lipinski’s Rule-of-Five violation which was for
logP (the octanol-water partition coefficient).4. Discussion
4.1. CMF-019 is the first evaluated biased small molecule agonist at the
apelin receptor
We have characterised and quantified the pharmacological
properties of a small molecule, CMF-019, predicted to bind to the
apelin receptor in a hydrophobic cavity near the SHK region of
bound apelin-13 in computational models. CMF-019 demonstrated
high affinity binding to native human, rat and mouse cardiac apelin
receptors, suggesting no evidence for species differences. In cells
expressing the human apelin receptor, CMF-019 had similar Gai
activity to [Pyr1]apelin-13 (RE = 4.19), however, for b-arrestin
recruitment and internalisation, it was much less potent
(RE = 0.01 and 7.19  104 respectively). CMF-019, thus, displayed
significant bias compared to the endogenous agonist [Pyr1]apelin-
13. This bias was towards the G protein signalling pathway, with a
bias factor of 400 compared to apelin receptor mediated b-
arrestin recruitment and 6000 compared to b-arrestin mediated
receptor internalisation. This is predicted to be beneficial in a ther-
apeutic setting as reduced receptor internalisation would allow for
maintained apelin signalling with repeated drug administration.
Indeed, our previously published work has shown that MM07, a
novel biased peptide agonist, induced reproducible dilatation in
the human forearm [4]. This work provided proof of concept forFig. 6. Cardiac contractility of CMF-019 in vivo. Dose dependent increases in left ventricu
n = 7–9) and (B) [Pyr1]apelin-13 (apelin, j, n = 8) compared to saline (d, n = 3–5) control
doses were administered cumulatively (*p < 0.05, **p < 0.01, ***P < 0.001).the merits of a biased agonist and our current work has focussed
on the investigation of a small molecule agonist with this desirable
pharmacological profile. CMF-019 is one of a larger series of apelin
agonists based on the benzimidazole scaffold [32] and these addi-
tional molecules may also display a similar bias profile.
To our knowledge this is the first report of bias for a small mole-
cule apelin agonist. To date, previous synthetic apelin agonists lack
desirable characteristics required of drug-like molecules. E339-
3D6, a reported peptidomimetic agonist did exhibit vasoactivity
in rat aorta preconstricted with noradrenaline and in vivo pre-
vented vasopressin release when injected intracerebroventricu-
larly in water-deprived mice [36]. However, the high molecular
weight (1400 Da) suggests it would be an unsuitable drug mole-
cule, particularly for oral dosing. Moreover, it was later shown to
be a mixture of polymethylated species from which a number of
analogues were subsequently purified [37]. These molecules, dis-
played low micromolar binding affinities for the apelin receptor
compared to CMF-019 which binds in the nanomolar range.
ML233, a small molecule of molecular weight of 359 Da, was lim-
ited by low solubility in saline at room temperature [38]. More-
over, the structure suggests that it would likely be a pan-assay
interference compound (PAINS) and have toxicity, including being
a Michael acceptor and having an activated quinone [34]. In con-
trast to these previously reported compounds, CMF-019 is more
drug-like and shows a good physiochemical profile when com-
pared to an oral drug library for Lipinski’s rules (Fig. 8A), Verber’s
rules (Fig. 8B) and in a PCA analysis of 15 physiochemical descrip-
tors (Fig. 8C). CMF-019 has one Lipinski’s Rule-of-Five violation
(logP), although this is ameliorated by the ionisation of the car-
boxylic acid at physiological pH, reducing the logD to a more
acceptable range (logD = 2.74 at pH7.4). Following the completion
of the in vivo studies, we detected a mean plasma concentration of
25 lM suggesting that CMF-019 is relatively stable with signifi-
cant compound remaining in the plasma after ten minutes. In con-
trast, the plasma half-life of [Pyr1]apelin-13 in rat has previously
been measured to be 2 min [4].4.2. CMF-019 affects cardiac action in vivo
We examined the effects of CMF-019 in vivowhen administered
to male Sprague–Dawley rats. We used the potassium salt of the
compound dissolved in saline at pH9 that showed better solubility
than the parent compound. CMF-019 caused a dose dependentlar contractility in anaesthetised rats to (A) intravenous CMF-019 potassium salt (N,
. Each dose was compared by a Student’s t-test to its corresponding saline control as
Fig. 7. Cardiovascular actions of CMF-019 in vivo. Graphs showing changes in stroke volume (A-B), cardiac output (C-D), relaxation (dp/dtMIN) (E-F) and left ventricular
systolic pressure (LVSP) (G-H) for CMF-019 potassium salt (N, n = 7–9, A,C,E,G) and [Pyr1]apelin-13 (apelin, j, n = 8, B,D,F,H) compared to saline (d, n = 3–5, A-H) when
injected intravenously into anaesthetised rats. Each dose was compared by Student’s t-test to its corresponding saline control as doses were administered cumulatively
(*p < 0.05, **p < 0.01, ***P < 0.001, ****P < 0.0001).
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Fig. 8. Assessment of drug-like properties of CMF-019 using FAF-Drugs3 [34]. (A) The properties of CMF-019 (HBD; H-bond donors; HBA, H-bond acceptors; logP, Octanol-
water partition coefficient; MW, molecular weight) are shown as a dark blue line. A compound library of oral drugs was also assessed for these characteristics to illustrate the
desirable physiochemical properties for a drug-like molecule according to Lipinski’s rules (light blue line). The red area denotes where it was not possible to have a molecule
with those properties, or where there was a lack of data in the library. (B) An oral absorption estimation for CMF-019 (dark blue line) (HBD; H-bond donors; HBA, H-bond
acceptors; RotB, rotatable bonds, logP, Octanol-water partition coefficient; MW, molecular weight; tPSA, topological polar surface area). A compound library of oral drugs was
also assessed for these characteristics to illustrate the desirable physiochemical properties for a drug-like molecule according to Verber’s rules (dark green line). The red area
denotes where it was not possible to have a molecule with those properties, or where there was a lack of data in the library. (C) An oral property space obtained by applying a
Principal Component Analysis (PCA) of 15 physicochemical descriptors of CMF-019 (shown as the red dot), compared to properties of oral drugs in current use, extracted as
sublibraries from the databases, eDrugs (blue) and DrugBank (orange). (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article.)
70 C. Read et al. / Biochemical Pharmacology 116 (2016) 63–72increase in dP/dtMAX, an index of increased cardiac contractility. A
similar response was observed for [Pyr1]apelin-13 and is consistent
with its role as an inotropic agent through the apelin receptor.
[Pyr1]apelin-13 also caused a decrease in LVSP, whereas, CMF-
019 caused an increase. The blood pressure response to [Pyr1]
apelin-13 can be explained by its action as a vasodilatory agent.
The fact that CMF-019 did not mirror [Pyr1]apelin-13 may simply
reflect its limited solubility and a higher concentration might be
required to observe an effect on the vasculature. Indeed, it was pre-
viously demonstrated that MM07, a novel G protein biased apelin
agonist, causes vasodilatation in forearm blood flow studies in
human volunteers [4]. Alternatively, the cardiac action of CMF-
019 may mask any vasodilator response. However, there is a report
that modified apelin-17 peptide fragments biased towards the b-
arrestin pathway are more able to induce decreases in blood pres-
sure [39] and this could explain the limited effects of CMF-019 on
the vasculature. [Pyr1]apelin-13 also increased cardiac output due
to an increased stroke volume rather than an increased heart rate.
CMF-019 similarly showed a trend to increase stroke volume and
cardiac output (with a significant effect observed at 500 nmol)
without a change in heart rate. [Pyr1]apelin-13 and CMF-019 did
not alter the dP/dtMIN, suggesting that neither had lusitropic
effects. Overall, the responses to CMF-019 showed a similar profile
to [Pyr1]apelin-13 and are consistent with it acting at the apelin
receptor in vivo, corroborating the in vitro data. Future studies will
look at the development of novel compounds to maintain the ben-
eficial bias profile whist improving solubility.4.3. CMF-019 is predicted to bind to a highly conserved region of the
apelin receptor
Analysis of the predicted binding region of CMF-019 within the
hydrophobic cavity near the SHK region of bound apelin-13 in
computational models revealed close proximity to the only
reported naturally occurring mutation in the apelin receptor to
date. In the zebrafish, Danio rerio, a single allele of a recessive
mutation, grinchs608, leads to a Trp85 to Leu85 amino acid change
in the second transmembrane domain and results in a complete
loss of apelin binding. As a consequence of this loss of function,
in the most severely affected mutants the heart fails to develop
[40]. Interestingly, in the SHK region of apelin-13 in our model is
the almost adjacent Tyr88 residue. Importantly, both residues havebeen conserved in humans and all species where apelin receptor
sequences have been reported, suggesting CMF-019 binds in a crit-
ical region of the receptor. Interestingly, in support of our proposed
model, a series of small molecule apelin agonists have been
reported [41] that share some structural similarity to CMF-019,
having two hydrophobic substituents extending from a hetero-
cyclic core, suggesting that they may bind to the same site of the
apelin receptor. It is not yet known if these compounds also display
receptor bias.4.4. Conclusions
CMF-019 is the first biased small molecule apelin agonist
reported and binds with high affinity to the apelin receptor in
human heart homogenate. Binding of CMF-019 was predicted
through molecular modelling to occur to a region in the apelin
receptor that, by comparison with other species, is highly con-
served and is crucial for interaction with the SHK amino acid
sequence of apelin-13. In rats, in vivo, CMF-019 produced a dose
dependent increase in cardiac contractility, corroborating its
in vitro activity.
Importantly, acute apelin infusion is beneficial in PAH and HF
and it is predicted that apelin agonists would display efficacy in
treating these conditions. We have previously designed apelin pep-
tide analogues that display bias towards the G protein signalling
pathway and have beneficial cardiovascular actions compared with
the native peptide in humans in vivo. Retention of bias towards G
protein signalling over b-arrestin recruitment/internalisation in a
small molecule should prove beneficial in a therapeutic setting
by reducing receptor downregulation following chronic use,
thereby preventing the need for dose escalation or patients becom-
ing refractory to treatment. Consequently, compounds based on
the structure of CMF-019 with an improved pharmacokinetic pro-
file could provide a novel and much needed therapy to treat PAH
and HF.Conflict of interests
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